Chronic lymphocytic leukemia patients with HLA-B27 referred for allogeneic hematopoietic stem cell transplantation do not have worse outcomes: Results of a population-based case series analysis in British Columbia, Canada

Autor: Lenka Allan, Helene Bruyere, Steven J.T. Huang, Alina S. Gerrie, Cynthia L. Toze, Jonathan Chan
Rok vydání: 2019
Předmět:
musculoskeletal diseases
Oncology
Adult
Male
Cancer Research
medicine.medical_specialty
medicine.medical_treatment
Chronic lymphocytic leukemia
Population
Hematopoietic stem cell transplantation
Human leukocyte antigen
Comorbidity
03 medical and health sciences
0302 clinical medicine
immune system diseases
hemic and lymphatic diseases
Internal medicine
Medicine
Humans
Transplantation
Homologous
Clinical significance
Public Health Surveillance
education
Alleles
HLA-B27 Antigen
Aged
HLA-B27
education.field_of_study
Ankylosing spondylitis
British Columbia
business.industry
Hematopoietic Stem Cell Transplantation
Myeloid leukemia
Hematology
Middle Aged
medicine.disease
Prognosis
Leukemia
Lymphocytic
Chronic
B-Cell
Survival Analysis
Treatment Outcome
030220 oncology & carcinogenesis
Case-Control Studies
Female
business
030215 immunology
Zdroj: Leukemia research. 84
ISSN: 1873-5835
Popis: Human leukocyte antigen B27 (HLA-B27), associated with spondyloarthritis, was suggested to be protective against chronic lymphocytic leukemia (CLL). It is hypothesized that HLA-B27 patients may have worse outcome in part related to their other comorbidities. Objectives We sought to compare the clinical characteristics and outcomes of CLL and small lymphocytic lymphoma (SLL) patients referred for allogeneic hematopoietic stem cell transplantation (allo-HSCT) based on their HLA-B27 status. Methods This retrospective population-based case series analyzed CLL/SLL patients who were HLA-typed for potential allo-HSCT in British Columbia, Canada. Results of 279 CLL/SLL patients referred for potential allo-HSCT, 34 patients were HLA-B27 positive. For HLA-B27 patients, median age at CLL diagnosis was 53.5 years (range, 27–67) and 71% were male. Seven patients had 11q deletion and nine patients had 17p deletion detected prior to first CLL therapy or at relapse. Eleven HLA-B27 patients received allo-HSCT. Two patients developed acute myeloid leukemia. One patient with ankylosing spondylitis had Richter’s transformation prior to any CLL therapy. Spondyloarthritis-related disorders were diagnosed in 12 HLA-B27 patients but there was no temporal correlation with development of CLL. Overall survival (OS) and treatment-free survival (TFS) were not significantly different between HLA-B27 patients with or without spondyloarthritis-related disorders. There were no significant differences in clinical characteristics at CLL diagnosis or OS/TFS between HLA-B27 positive and negative patients referred for allo-HSCT. Conclusions HLA-B27 positivity does not appear to influence outcome for CLL/SLL patients referred for allo-HSCT. Further studies are needed to evaluate the clinical significance of HLA-B27 in a general CLL population.
Databáze: OpenAIRE
Externí odkaz: